Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €9.42 EUR
Change Today +0.197 / 2.14%
Volume 0.0
B9M On Other Exchanges
As of 8:15 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

btg plc (B9M) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/25/15 - €11.90
52 Week Low
08/11/14 - €7.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BTG PLC (B9M)

Related News

No related news articles were found.

btg plc (B9M) Related Businessweek News

No Related Businessweek News Found

btg plc (B9M) Details

BTG plc, a specialist healthcare company, acquires, develops, and commercializes pharmaceutical products worldwide. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers oncology products, including Beads and TheraSphere for the treatment of liver tumours; pulmonology products comprising RePneu Coil system for the treatment of emphysema; and vascular products, such as EkoSonic for severe blood clots, as well as Varithena for moderate to severe varicose veins. The Specialty Pharmaceuticals segment provides acute care and antidote products, such as CroFab for crotalid snakebites; DigiFab for digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment offers Abiraterone acetate for advanced prostate cancer; Alemtuzumab for multiple sclerosis; and Two-Part Hip Cup for hip replacement. BTG plc is also developing uridine triacetate that is in late-stage of clinical trials for life-threatening toxic side effects of overexposure to the chemotherapeutic 5-fluorouracil. The company also manufactures and commercializes therapeutic ultrasound devices. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

1,121 Employees
Last Reported Date: 05/18/15
Founded in 1948

btg plc (B9M) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.1M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 707.0K GBP
Compensation as of Fiscal Year 2015.

btg plc (B9M) Key Developments

BTG plc Provides Earnings Guidance for the Fiscal Year 2016

BTG plc provided earnings guidance for the fiscal year 2016. For the year, the company announced that a strong performance in the 2014/15 financial year, the business has made a good start to the current financial year with overall trading in line with expectations. As previously announced, the company's full year revenue is expected to be in the range £410 million to £440 million.

BTG plc Announces Treatment of First Patient in Singapore with Therasphere Radioembolization Therapy

BTG plc announced the treatment of the first patient in Singapore with TheraSphere, a treatment for primary liver cancer and metastatic colorectal cancer, specifically engineered to deliver powerful doses of radiation to the tumour while minimizing exposure to normal tissue. TheraSphere is a targeted therapy that consists of millions of glass microspheres containing radioactive yttrium-90. The microspheres are about 20-30 micrometers in diameter, about a third of the width of a human hair. They are delivered directly to liver tumours through the hepatic artery using a catheter. The glass microspheres flow directly into the liver tumour through its blood vessels and become permanently lodged there. Because the procedure delivers the treatment directly to the liver tumour, the radiation destroys the tumour cells with minimal impact to the surrounding healthy liver tissue. The radioactive microspheres continue to deliver radiation to the tumour over the course of several weeks after treatment. TheraSphere can also be used as a bridge to surgical removal of diseased tissue or transplantation in these patients.

BTG plc Announces Revolens Study Results

BTG plc announced the presentation of top line data showing that REVOLENS, a randomized, controlled trial sponsored by the French Ministry of Health, met its primary endpoint. The results show that the PneumRx endobronchial coil is superior to the standard of care for improving exercise capacity in patients with severe emphysema at 6 months as measured by the 6 minute walk test (6MWT). The results were presented by Professor Gaetan Deslee of the University Hospital of Reims, France at the American Thoracic Society (ATS) International Conference in Denver, Colorado. The REVOLENS study randomized 100 patients with severe emphysema from 10 centres in France. The primary outcome measure was the rate of patients showing an improvement greater than or equal to 54 metres distance in the 6MWT at 6 months. An intention to treat analysis showed that the rate of patients meeting the primary endpoint was superior in the coil group (36%) compared to the standard of care group (18%) (P<0.05). REVOLENS (réduction de volume par voie endobronchique par spirales) was a prospective multicenter randomised controlled superiority trial comparing coil treatment with the standard of care in severe emphysema. The study was funded by the French Ministry of Health under the soutien aux techniques innovantes couteuses (STIC) program, which provides government funding for innovative medical technologies that have been validated by prior clinical studies, with a view toward establishing reimbursement for new devices. Developed by PneumRx, a BTG group company, the endobronchial coil is a minimally invasive device intended to improve exercise capacity, lung function, and quality of life for severe emphysema patients. The device has a CE Mark and has been used in Europe for the treatment of emphysema since 2010. Coil treatment is being studied under an Investigational Device Exemption (IDE) in the United States and is not yet approved for commercial use by the FDA. The RENEW Clinical Study, a Phase III pivotal trial of 315 patients completed enrolment in October of 2014 and a US regulatory submission is planned for 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B9M:GR €9.42 EUR +0.197

B9M Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Impax Laboratories Inc $48.42 USD -0.83
Merit Medical Systems Inc $24.85 USD -0.79
Pfizer Ltd/India 2,122 INR -12.90
RPX Corp $15.33 USD -0.78
Medicines Co/The $30.95 USD -2.53
View Industry Companies

Industry Analysis


Industry Average

Valuation B9M Industry Range
Price/Earnings 77.5x
Price/Sales 7.1x
Price/Book 3.5x
Price/Cash Flow 43.1x
TEV/Sales 7.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at